{
  "id": 18585900,
  "title": "Gilead Sciences CEO O’Day sells $19.7 million in company shares",
  "url": "https://urgent.news/2026/11/06/gilead-sciences-ceo-oday-sells-19-7-million-in-company-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-06T22:46:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/gilead-sciences-ceo-oday-sells-197-million-in-company-shares-93CH-5009359"
  },
  "original_language": "en",
  "account": "On November 4 and 5, 2026, Daniel O’Day, the CEO of Gilead Sciences, sold approximately $19.7 million worth of company shares. The sales were executed in accordance with a pre-established Rule 10b5-1 trading plan. Simultaneously, O’Day exercised stock options, buying shares totaling around $8.1 million. On November 4, he sold 102,619 shares priced between $175.05 and $175.35 per share. The next day, November 5, he sold an additional 9,810 shares at an average price of $175.17 per share, totaling around $19,693,438. The sale prices were close to Gilead’s 52-week high of $176.58, with the stock having returned 39% year-to-date. However, experts suggest the stock might be overvalued at the moment. Concurrently, O’Day purchased 112,429 shares through option exercises, acquiring them at $72.34 each, worth about $8,133,113. Now, he holds 551,683 shares directly and retains 128,310 non-qualified stock options, expiring on March 10, 2030, with a vesting schedule over four years. Gilead Sciences reported strong quarterly results, generating $8.3 billion in revenue, exceeding analyst estimates by 6%, and earning $2.55 per share, surpassing expectations by 15%. This marks the company's strongest growth in over a decade, with a 16% increase year-over-year. Investment firms UBS, TD Cowen, and BMO Capital recently raised their price targets for Gilead Sciences, citing robust performance in the HIV portfolio and liver products, as well as a higher gross margin. Analysts remain optimistic about Gilead's financial health and growth prospects.",
  "summary": null,
  "key_points": [
    "Gilead CEO Daniel O’Day sold $19.7M in shares on Nov 4-5, 2026",
    "Sold 102,619 shares at $175.05-$175.35 per share Nov 4",
    "Exercised stock options to buy $8.1M worth of shares Nov 5"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}